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Abstract
Recently, researchers have identified a number of anti-HIV broadly neutralizing
antibodies (bNAbs), such as VRC01 and N6, capable of targeting a broad range of HIV-1
strains. Passive immunization using these patient-derived bNAbs could provide temporary
protection but are limited by the short antibody half-life. While current gene transfer
technology allows sustained bNAb expression, it lacks the ability to control bNAb production
in vivo resulting in possible autoimmunity. To address this issue of achieving controlled bNAb
expression in vivo, we hypothesize that bNAb expression from transduced Flu-specific B cells
can be activated and modulated by subsequent Flu immunizations in the Flu-preimmunized
animal. In this preliminary study, we have constructed a bNAb (N6 and VRC01) -expressing
murine retroviral vector (MIGR) and successfully transduced Flu-specific primary B cells.
Following transfusion of these cells into Flu-immunized recipient mice, we observed an
anamnestic N6 antibody response with subsequent Flu immunizations.

Keywords
HIV-1, broadly neutralizing antibodies, gene transfer therapy, immunotherapy, controlled
endogenous antibody expression
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Lay Summary
After more than 33 years of effort there is still no effective HIV vaccine to prevent
transmission, and passive immunization cannot provide persistent protective antibody. Thus,
gene transfer, especially utilizing retroviral vector technology, has become a very hot topic in
the field due to its ability to confer continuous protective antibody production. However,
continuously expressed broadly protective antibodies have autoimmune potential. Therefore,
a more controlled method of antibody expression is necessary. In this study, we utilized a Flu
preimmunization strategy to modify a specific type of immune cell, i.e. B cell, to provide an
ideal means to modulate expression of broadly protective anti-HIV antibodies; effectively
combating HIV infection while avoiding possible side effects. Specifically, Flu-specific B
cells were isolated from immunized mice and an anti-HIV antibody gene, VRC01 or N6,
were incorporated using a retroviral vector. These B cells were then transfused back into the
Flu immunized mice followed by boosts with Flu vaccine. We observed that N6 expression
increased after subsequent Flu immunizations, providing a proof-of-concept for our strategy.
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Introduction
The causative agent of acquired immunodeficiency syndrome (AIDS) is Human

Immunodeficiency Virus (HIV), a lentivirus from the Retroviridae family(1). Individuals
with AIDS experience a steady depletion in CD4+ T cells, rendering them severely
immunocompromised (2) and susceptible to opportunistic infections (3). According to the
2018 UNAIDS report, 32 million people have died from AIDS-related illnesses since the
start of the epidemic, approximately 37.9 million people are living with HIV, and 1.7
million new infections are reported annually. Nevertheless, several breakthroughs have
been made to overcome this disease. The development of anti-retroviral therapy (ART) has
had major implications in the field by decreasing HIV-associated morbidity and mortality
(4–6). Effective viral suppression by ART improves immune function, subsequently
reduces AIDS-related complications, and improves the overall quality of life (7–9). Despite
its positive implications, it is limited by its inability to cure the disease. In most cases,
untreated individuals do not survive, enforcing a lifelong dependence on ART. This can
raise significant concerns on the sustainability and affordability of ART, especially since
the most heavily hit regions are among some of the poorest countries in the world (10).
Instead, a cure or vaccine would undoubtedly reduce such concerns while increasing the
overall health benefits (11). Some individuals with a chronic HIV infection develop
broadly neutralizing antibodies (bNAbs), termed so based on their ability to neutralize a
wide range of HIV-1 strains. While vaccine strategies have failed to elicit bNAbs, passive
immunization and gene transfer therapy have shown promise in HIV treatment. Although
passive immunization is a promising avenue for bNAb application in preventing or treating
HIV-1 infection, its use is limited due to the short half-life of bNAbs, thus requiring
multiple administrations of expensive, immunotherapy-grade antibodies. On the other
hand, while gene transfer therapy allows for long-term expression of bNAbs, their levels
are uncontrolled. It has been widely reported that bNAbs have the potential of crossreacting with self-antigens; the combination of long-term, high levels of bNAb expression
and reactivity to self-antigens creates the potential for harmful autoimmunity. Our work
will try to work around this problem by creating a means to control in vivo expression of
bNAbs.
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1.1 HIV-1 Envelope, home of a small conserved oasis of
antibody-based targets
1.1.1

HIV-1 Structure and Envelope
The HIV-1 genome consists of two copies of single stranded RNA surrounded by

a capsid and by a viral membrane. Situated on the outer membrane are envelope
glycoproteins that are incorporate into the virions as they bud from the host cell. The
envelope glycoprotein of HIV-1 is synthesized in the rough endoplasmic reticulum and
processed into gp120 and gp41via cleavage by host protease furin (12, 13). Surface gp120
and the transmembrane gp41, associated noncovalently, are determinants of viral tropism
and are involved in the promotion of viral and host cellular membrane fusion by
recognizing and interacting with particular receptors(14). Specifically, Env gp120 serves
as the receptor-binding component and engages CD4 and a coreceptor (CCR5 or CXCR4),
while gp41 serves as a means for viral core entry into the host cell(15). The successful
binding and entry of HIV involves several conformational changes that expose conserved
regions of the virus and typically occurs in a two-step process outlined in detail by Wilen
et al (15). Briefly, CD4 binding to the constitutively accessible CD4 binding site (CD4bs)
on gp120 induces a conformational change, which triggers both high affinity CD4 binding
and structural rearrangement of the Env trimer to reveal the chemokine-receptor binding
site (15). The exposure of chemokine-binding site promotes further engagement by gp120
and induces another conformational rearrangement of the Env trimer, triggering gp41
activation(15). The consequent refolding of gp41, as a result of its activation, induces viral
and target cell membrane fusion and subsequent deposition of the viral core within the
target cell(15). Env proteins are amongst the most immunogenic components of HIV-1
particles as they are expressed on the viral membrane(16, 17). Although the ability of HIV1 to rapidly mutate its genome enhances antigenic variation of surface glycoproteins, the
domains that bind to CD4 and coreceptor are highly conserved (18). gp120 possesses five
conserved regions (C1-C5) that are interspersed between five regions of considerable
sequence variability, often called hypervariable loops (V1-V5) (18). The variable regions
occlude the constant regions, thus antibodies are primarily raised against variable regions
rather than conserved regions (18). Furthermore, gp120 contains approximately 25 N-
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glycosylation sites that form a glycan shield, which serves as another mechanism to
overcome immune defenses (18).

1.1.2

Classes of humoral immune response against Env
Antibody responses to the HIV-1 envelope glycoproteins can be classified into

three groups based on their ability to target and neutralize a range of HIV-1 strains (Figure
1) (19). The first group of antibodies is unable to neutralize viruses, including those with
Env sequences identical to the immunizing antigen (19). However, it is still likely that such
non-neutralizing Ab (nNAb) can perform antiviral function through Fc-mediated activities
(19). Antibodies bound to the Env proteins can attach to FcγR expressed on innate immune
cells and trigger Ab-dependent cellular cytotoxicity (ADCC) and Ab-mediated cellular
phagocytosis (ADCP). ADCC is mediated by natural killer effector cells, whereas
monocytes, macrophages or dendritic cells that can internalize Ab-bound virus or Abcoated cells are responsible for ADCP(20). These two Fc-mediated processes are
dependent on IgG subclass and Fc glycosylation, with some mutations of the Fc region,
such as the removal of the Fc glycan fucose residues, increasing the effectivity of
ADCC(19).
The second group of antibody responses encompasses antibodies that neutralize
virus but in a highly strain-specific, autologous, manner. Often, these antibodies exert
selective pressures that drive viral resistance to the humoral response. Consequently, they
promote survival of escape variants that have been generated via insertion/deletion
mutations in gp120 variable regions through amino acid substitutions and changing surface
glycosylation sites (16, 17, 21, 22).
The third group of antibodies is associated with a response able to neutralize a wide
array of HIV-1 strains and is therefore termed broadly neutralizing antibodies (bNAbs). In
vitro, bNAbs have been demonstrated to neutralize the majority of HIV-1 strains with a
half maximal inhibitory concentration (IC50) of less than 1 μg/ml (19, 23). The known
spectrum of bNAb targets encompass the CD4bs (24, 25), glycan dependent epitopes
V1/V2 and base of V3/C3 (26–29), and linear epitopes in the membrane proximal external
region (MPER) of gp41(30). The ability of bNAbs to target conserved regions derives from
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years of continuous affinity maturation. This endows them with mechanisms to cope with
the variability that surrounds the small regions of conserved Env trimer (19).

Figure 1. Representation of some forms of Env targets present on infecting HIV-1
strain and available to elicit their respective class of antibody response.
For an anti-HIV antibody to have neutralizing activity, it should interact with functional
spikes on Env trimers that mediate HIV entry into target cells (19, 31). Non-neutralizing
antibodies typically target Env epitopes absent from the functional spikes of the native Env
trimer (19, 32). The targets for autologous nAbs are V loops and other regions of gp120
with relatively high sequence variation on functional spikes between strains, and therefore,
they can only bind Env trimers from the infecting strain. Heterologous bNAbs on the other
hand typically target the relatively conserved regions, based on sequence or amino acid
homology, with some targeting the variable loop. Collectively, the known spectrum of
bNAb targets encompass the CD4bs (25, 33–36), glycan dependent epitopes V1/V2 and
near the base of V3/C3 (26–29), and linear epitopes in the membrane proximal external
region (MPER) of gp41(30). Image created using BioRender.
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1.1.3

HIV diversity and complications
It is widely believed that the holy grail of HIV-1 prophylactic vaccine development

is an envelope-based immunogen that elicits bNAbs against a wide array of HIV-1 strains.
Unfortunately, despite 35 years of thorough investigation, no effective Env immunogen
has been discovered or generated that can elicit broadly neutralizing activity, and partly,
this failure is attributed to the various immune evasion mechanisms that HIV-1 employs
(32, 37). One such mechanism is the extreme genetic diversity of HIV-1 (38), which is
attributed to the highly error-prone reverse transcriptase, a high tendency for recombination
driven by the constant evolutionary pressure of avoiding detection and destruction by the
immune system, and an extremely rapid turnover in vivo (39, 40). Genetic variation of this
retrovirus resulted in four distinct groups of HIV-1: M, N, O and P. Group M is further
subdivided into nine distinct subtypes (A-D, F-H, J, and K) and numerous additional
circulating recombinant forms (CRFs) (40, 41). Some of these CRFs have recombined with
other subtypes or other CRFs to form “second generation” recombinants (42). Genetic
interclade diversity ranges from 20-30%, diversity within clades reaches as high as 12%,
and circulating viruses can differ within the highly variable envelope protein by up to 38%
(39, 43). This vast diversity makes it difficult to design an immunogen that can account for
all existing variants of HIV-1. Moreover, HIV-1 utilizes host-derived, non-immunogenic
glycans to mask its envelope to evade immune recognition (44–46). Nearly 50% of Env’s
molecular mass is composed of host derived N-linked sugars, and such carbohydrate
moieties prevent immune recognition by occluding highly immunogenic epitopes on gp120
(16, 47). The role of Env glycans in attenuating recognition by immune cells has been
demonstrated in several studies where removal of specific glycans in V loops, within C2C4 region, and gp41 exposed relevant bNAb epitopes (48–50). In one such study, rhesus
monkeys infected with Simian Immunodeficiency Virus (SIV) mutants lacking
glycosylation in the V1 region of gp120 resulted in the production of higher neutralizing
antibody titers than those infected with wildtype SIV (51). Specific to the recessed pocket
on gp120 containing the CD4bs, removing glycans peripheral to it increases the sensitivity
of the virus to neutralization (52–54).
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1.2 Patient-derived anti-HIV-1 bNAbs and nNAbs
1.2.1

Mechanisms for generation of bNAbs
During chronic HIV-1 infection, up to 50% of infected individuals produce high

levels of neutralizing antibodies (nAbs) against Env (55–57). Among these patients,
approximately 1% are “elite neutralizers” and produce bNAbs, typically after 2-4 years of
infection (58). B cell affinity maturation is one of the proposed methods for the humoral
system development of bNAbs. The B cell repertoire consists of follicular (FO) B cells,
marginal zone (MZ) B cells, plasmablast and plasma cells, as well as memory B cells. FO
B cells, which are mature but inactive, are the most common type of B cells (59). They
recirculate in the blood and can become either antibody-producing plasma or memory B
cells with help from cognate T cells upon antigen exposure, generating the majority of
high-affinity antibodies during an infection. Memory B cells are dormant B cells that arise
from B cell differentiation following prior antigen recognition and T cell help (60). During
HIV-1 infection, these memory B cells go through multiple rounds of affinity maturation
which allows for the gradual recognition of viral variants that emerge over time and leads
to the potential production of bNAbs (Figure 2) (61–65).
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Figure 2. Germinal center reactions that can lead to the production of anti-HIV
bNAbs.
HIV-1 specific B cells undergo proliferation and somatic hypermutation of the BCR in the
dark zone, followed by affinity selection in the light zone. The resulting cells compete for
the limited Tfh cell help, and cells with a high affinity BCR gets more help than those with
a low affinity BCR, which consequently undergo apoptosis. The surviving cells can either
differentiate into plasma cells, re-enter the GC for additional rounds of somatic
hypermutation and proliferation, or differentiate into memory cells. Re-entry of these
memory cells with stimulation from other Env variants will allow for further affinity
maturation. These events form the cycle needed to generate anti-HIV-1 bNAbs.
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Germinal centers (GC) are the conveyors of affinity maturation. GCs consist of
antigen-specific B cells that undergo proliferation and multiple rounds of somatic
hypermutation of the B-cell receptor (BCR) in the dark zone, and subsequently selection
in the light zone. Here, a fraction of the selected B cells returns to the dark zone for
additional proliferation and rounds of mutations (66). Mutations in the BCR can alter its
affinity towards its specific antigen. B cells possessing a high affinity BCR will capture
more antigens and consequently express more antigen derived peptide on its MHC-II, and
thus receive more help from follicular helper T cells (Tfh cells) (67, 68). Tfh cell help
involves many molecules including CD40L, IL-21, IL-4, CXCL13, and SLAM.
Collectively, help provided by Tfh cells contribute to the survival, proliferation, somatic
hypermutation, and isotype class switching of GC B cells, all of which combine to select
for high affinity B cells clones by Tfh cells (67). GC Tfh cells are not only necessary but
also limiting in the production of HIV bNAbs. In a study of a human cohort, using a
combination of Tfh cell surface markers to track Tfh cells, the authors demonstrated a
correlation between frequency of memory Tfh cells and anti-HIV bNAb generation (69).
Similarly, at the primate level, SIV and Simian-Human Immunodeficiency Virus (SHIV)
challenge studies in rhesus macaques have also shown an association between Tfh cells
and generation of neutralizing antibody breadth. Additionally, rhesus monkeys with the
highest frequency of GC Tfh cells developed the highest SIV Env-specific antibody titers
(70). Another study postulates that increasing the magnitude of HIV-1-specific Tfh
response, or the breadth of the Tfh repertoire, can facilitate the evolution of anti-HIV
bNAbs (71).
The key players and complex interplay of genetic factors predisposing to bNAb
development are still being investigated, however, predisposition to natural control of HIV1, evident in elite neutralizers, involves HLA-I alleles that allow for a robust CD8+ T cell
response. Inherently, characteristics of the immune system actually limit the development
of bNAbs.

The relatively long heavy chain complementarity determining region 3

(CDRH3) typical of bNAbs, are generated at the stage of V(D)J recombination, and
therefore restricting the human immunoglobulin repertoire in the variety of specific V(D)J
rearrangements encoding germline precursors of HIV-1 bNAbs. This in turn explains the
rarity of their presence. Conversely, the accumulation of a large number of mutations,
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generated by somatic hypermutation during multiple cycles of affinity maturations are also
difficult to sustain (61).

1.2.2

First generation bNAbs
The first generation anti-HIV bNAbs were discovered in the early 1990s when

researchers found antibodies capable of neutralizing different HIV-1 subtypes. These
bNAbs were isolated by using phage display or human hybridoma electrofusion. The first
generation bNAbs include 447-52D (targeting the V3 loop), b12 (targeting the CD4bs),
17b (targeting the co-receptor binding site), 2G12 (targeting viral glycan), 4E10 and 2F5
(targeting the gp41 MPER) (Table 1) (72). Studies carried out with HIV-1 pseudoviruses
of different subtypes have demonstrated that first-generation bNAbs exhibit low to
moderate breadth and neutralization potencies (18). Therefore, achieving the desired
efficacy as a therapeutic requires high concentrations of these bNAbs, with an inherent
limitation to the range of HIV-1 isolates that can be neutralized. The first generation of
bNAbs had additional undesirable characteristics that impede their therapeutic
applications. Firstly, 2G12 has three antigen combining sites instead of the usual two (72),
and its target epitope is conformation-sensitive based on asparagine glycosylation of Env
regions (18). Moreover, 2F5 and 4E10 are cross-reactive to self-antigens and b12 is a
phage-derived Fab-fragment Ab generated by random pairing of heavy and light chains
that may have never existed in nature (72).
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Table 1. Categories, efficacies, and research development of broadly neutralizing
HIV-1 antibodies.
Target
Site

Antibody
designati
on

CD4bs

V1/V2
loop

V3
loop

Gp41
MPER

VRC01

*Neutraliz
ation
Potency
(μg/ml)
0.250

**Neutr
alization
breadth
%
91%

HJ16
B12

1.16
1.79

36%
40%

CH103

4.54

55%

N6
PG9

0.044
0.109

98%
78%

PGDM140
0

0.015

83%

PGT145

0.3

78%

PGT121

0.07

70%

10-1074

0.036

2F5
4E10
10E8

1.44
1.303
0.222

Similar
monoclon
al
antibodies
VRC02,
VRC03,
VRC23,
NIH45-46,
3BNC60,
BNC62,
3BNC117,
12A12,
12A21,
12A30,
VRC-PG04
VRC-CH31
?
?

Year of
Generatio
n

Referenc
es

2010

Research
and
developm
ent stage
Phase 2b

2010
1991

?
Preclinical

(77)
(34)

2013

?

(78)

2016
2009

Preclinical
?

(73, 79)
(73)

2014

Preclinical

(73, 76,
80)

2011

?

2011

Preclinical

66%

CH104,
CH105,
CH106
?
PG16
CH01
PGDM1401
PGDM1406
PGT141 to
PGT144
PGT122
PGT123
?

2012

Phase 1

(25, 27,
81)
(25, 76,
81, 82)
(73, 76)

67%
98%
98%

m66
?
7H6

1992
1994
2012

Phase 1
Phase 1
Preclinical

(83–85)
(73, 86)
(30, 73)

(34, 73–
76)

*For neutralization potency, the geometric mean value among neutralized viruses is
shown
**breadth as the percentage of viruses neutralized by at least 50% at IC50.
? = unable to find in literature
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1.2.3

Second generation bNAbs
The discovery of high throughput single-cell B cell receptor (BCR) amplification

and novel soluble Env selection tools, together with the ability to isolate and culture
memory B cells in vitro, has permitted identification and isolation of second generation
bNAbs from chronically infected HIV-1 patients (26, 76). Second generation bNAbs are
more potent and have a broader coverage of HIV-1 strains (26, 76).
Somatic variants PG9 and PG16, discovered in 2009, were among the first second
generation bNAbs identified to target the gp120 V1/V2 loops. Characteristic features of
antibodies targeting the V1/V2 loops include exceptionally long complementaritydetermining region 3 (CDRH3) arms to penetrate through the gp120 glycan shield to access
the protein surface beneath (18). They also tend to interact with glycans at N160 and, to a
lesser extent, N156 (18). PG9/PG16 neutralization activity is dependent on both
interactions with amino acid residues within V1/V2 loops as well as N-glycosylation sites
at N160 and N156 (26). The CDRH3 arm of PG9 and PG16 is composed of a long loop of
30 amino acid residues, and its negative charge contributes to interactions with positivelycharged glycans at N160 and N156 (26). Overall, PG9 (IC50 of 0.109 μg/mL) and PG16
(IC50 of <0.12 μg/mL)possess notable neutralization breadth and potency, capable of
neutralizing 78% and 73% of pseudoviruses tested, respectively (26). CAP256 also has a
long CDRH3 loop that binds to a quaternary epitope within V1/V2 region, however it is
highly specific for residues 159-171 in the V2 loop that make up the FN/LRD-K-K motif
(87). PGDM1400, isolated more recently in 2014, also interacts with the gp120 V1/V2
quaternary epitope and exhibited high breadth (neutralized 83% of tested pseudoviruses)
and remarkable potency (median IC50 of 0.003 μg/mL) (88).
A number of broad and potent bNAbs that target the V3 loop region have been
described, including PGT121, PGT128, PGT135, and 10-1074 (29,101,102). The highmannose glycans on N332 are commonly targeted by these bNAbs, and they too possess
long CDRH3 loops to penetrate the gp120 glycan shield (18). PGT121(IC50 of 0.07
μg/mL) utilizes a unique mode of action of neutralization by inhibiting CD4 binding to
gp120 through allosteric mechanisms (18). PGT121 and 10-1074 (IC50 of 0.036 μg/mL),
in contrast to the other V3 loop-targeting bNAbs, bind to complex-type rather than high-
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mannose glycans on gp120 (28). PGT121 has a greater breadth of neutralization than 101074. PGT121 can neutralize 70% of tested pseudoviruses, whereas 10-1074 can neutralize
66% of tested pseudoviruses.
Another major site of vulnerability that bNAbs can target is gp41 MPER. 10E8 is
an MPER-specific antibody that demonstrated ability to neutralize 98% of tested
pseudovirions at an IC50 of <50 μg/mL (30). 10E8 (IC50 of 0.222 μg/mL) possesses a 22amino-acid long CDR H3 loop that makes contacts with highly conserved hydrophobic
gp41 residues, along with a narrow band of residues from CDRH1 and CDRH2 (30).
Antibodies that bind to the CD4bs are among the broadest, reaching coverage of up
to 98% against cross clade viruses (79). VRC01, VRC02, and VRC03 were isolated in
2010 from an HIV-infected individual living with untreated infection for over 15 years
(34). These three bNAbs are highly somatically mutated somatic variants. While VRC01
and VRC02 are somatically mutated variants of the same IgG1 clone with identical heavy
chain CDR3 regions, VRC03 likely originated from a different IgG1 clone although
derived from the same heavy chain alleles as VRC01 and VRC02 (34). It has been
demonstrated that VRC01 can neutralize 91% of the tested pseudovirions (of 190 Envpseudotyped viral strains representing all major clades and circulating recombinants) at an
IC50 of <50 μg/mL, and neutralize 72 % of primary isolates at an IC50 of <1 μg/mL (34,
76). VRC02 exhibited similar properties as VRC01, however VRC03 was much less broad
than VRC01 and VRC02, neutralizing 57% of the pseudovirions at an IC50 of <50 μg/mL.
VRC01 and VRC02 interact with CD4bs on gp120 by mimicking the interaction of CD4
with gp120, however instead of inducing structural conformations, the antibodies trap
gp120 in a state that prevents viral entry (34). This mechanism of targeting contributes to
the high neutralization potency demonstrated by VRC01 (34).
Following the discovery of VRC01, numerous other CD4bs-targeting antibodies
were identified, including NIH45-46, 3BNC117, and 12A12. NIH45-46 is a more potent
clonal variant of VRC01 with high sequence and structural similarities to VRC01, yet it
has a distinct mode of binding to gp120 (25). An amino acid substitution from glycine (G)
to tryptophan (W) at position 54 of NIH45-46 yielded NIH45-46G54W (25). This mutation
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increased the interactive surface between NIH45-46G54W and gp120, which resulted in
enhanced potency and breadth (25). For many years since its discovery in 2011, 3BNC117
(IC50 of 0.84 μg/mL) had the greatest potency and breadth of all the CD4bs-targeting
second generation bNAbs; majority of tested viruses were more sensitive to 3BNC117 than
VRC01 (33). 3BNC117 is currently being tested in phase 2 clinical trial (NCT02446847)
to evaluate its safety and potential in preventing or delaying viral load rebound during ART
treatment interruption. Recently discovered monoclonal CD4bs antibody, N6, is the most
potent bNAb described thus far, and has one of the highest neutralization breadths;
however, it hasn’t been studied to the same extent as VRC01 and other CD4bs bNAbs (73).
In a study involving 181 pseudoviruses from various clades, N6 was able to neutralize 96%
of viruses at a median IC50 of 0.038 μg/ml (73). Focusing on clade C pseudoviruses, N6
neutralized 98% of 171 at a median IC50 of 0.066 μg/ml (73). N6 has a unique mode of
Env recognition, including its ability to avoid steric clashes with the highly glycosylated
V5 region as well as ability to tolerate loss of antibody contacts with the CD4bs or V5
region (73). These properties enable N6 to overcome major mechanisms of resistance, thus
allowing for the neutralization of many isolates that were resistant to VRC01 and other
CD4bs antibodies (79).

1.3 Application of bNAbs: an arsenal of protective potential
1.3.1

Eliciting a bNAb response using immunogens
In an attempt to effectively elicit a broad humoral immune response, various

vaccine strategies have been explored, including designing of consensus or ancestral
proteins (89–92), modifying Env variable regions or glycosylation sites (89, 92), and
replicating Env-CD4 fusion transient intermediates (89, 93). To overcome HIV diversity
in particular, a frequently used method is the sequential immunization strategy. This
strategy revolves around the idea that by sequentially exposing a subject to a collection of
Env variants representing the viral quasispecies isolated from an individual that developed
bNAbs, the subject might be able to undergo a virtually identical humoral response. Using
diverse Env proteins would drive antibody maturation by presenting new epitopes and thus
focusing the humoral response on more conserved epitopes (89).
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Alternatively, a novel vaccine priming strategy that emphasizes germline targeting
to initiate affinity maturation of specific germline-precursor B cells has been of great
interest. Using Env-based immunogen designs, this strategy allows for immunofocusing
by preferentially activating bNAb-precursor B cells, subsequently allowing for productive
bNAb-like somatic mutations, and ultimately resulting in the production of memory B cells
that can be boosted with Env immunogens to select for additional productive mutations
(94–96). In some cases, inferred germline (iGL) bNAb precursors have high affinity for
native Env from particular HIV isolates (97, 98), simplifying the design of priming
immunogens to be derived from Env of these isolates (99). For other iGL bNAb precursors,
no such wild-type Env has been found to bind with high affinity, thus requiring the design
of modified Env as the priming immunogen (100, 101). An example of such an immunogen
is the eOD-GT8 molecule which has been designed and selected to bind with varying
affinity to various iGL versions of VRC01-like bNAbs (94). The efficacy of designed
priming immunogens has been evaluated in immunization experiments in mouse models
that have been engineered to have the precursor form of VRC01 IgH or IgL genes
integrated into the corresponding mouse Ig loci. Using these “knock-in” mice, a single
eOD-GT8 immunization was demonstrated to stimulate the production of a VRC01-class
memory response in at least 29% of the immunized mice despite the presence of a low
frequency of VRC01-class precursor per mouse (102). It is expected that after the priming
of germline precursor, a potent induction of bNAbs will require sequential boosts, driving
a succession of germinal-center reactions to select sufficient mutations (103). Despite such
consistent efforts, a gold-standard immunogen or vaccination method that can elicit
broadly reactive and potent nAbs has not been identified.

1.3.2

Passive immunization
As an alternative to vaccine development, passive immunization is being explored

as a potential therapeutic for treatment and prevention of HIV-1 infection. Passive
immunization involves the transfer of active humoral immunity of purified antibodies to
nonimmune individuals. In early preclinical animal studies involving passive transfusion
of HIV-1 neutralizing sera and first generation bNAbs, relatively effective protection was
conferred against certain HIV-1 strains. However, due to the poor breadth and potency of
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first generation bNAbs, and primarily the cost of manufacture, passive immunization was
not pursued further (104). Nevertheless, with the discovery of more potent and broader
second generation bNAbs, such as VRC01 and its clonal variants, research into passive
immunization has resurfaced and has demonstrated prevention and treatment potential
against lentiviral infection in macaques, humanized mice, and humans (105, 106, 115, 107–
114). In one such study, intravenous transfusion of PGT121 mediated sterilizing immunity
against Simian-Human Immunodeficiency Virus (SHIV) in monkeys at lower
concentrations than those observed in previous studies (105). Similarly, VRC01 infused
monkeys conferred complete protection against high-dose vaginal and rectal SHIV
challenge (116). In contrast to a high-dose challenge model, humans are typically exposed
to small but multiple doses of HIV via a mucosal route. Macaques subjected to intrarectal
challenge post single dose VRC01 transfusion conferred protection for up to 23 weeks, and
protection was proportional to antibody concentration and half-life (112). Two V2-specific
antibodies, PGDM1400 and CAP256-VRC26.25, have demonstrated high potency and
neutralization breadth against HIV-1 (117). Not much exploration has been pursued into
V2-specific bNAbs, however PGDM1400 has been shown to be fully protective at
0.4mg/kg dose against SHIV challenge in a macaque model (117). Similarly, CAP256VRC26.25 conferred complete immunity at a smaller dosage of 0.08 mg/kg, and thus
showing the potential for V2-specific bNAbs as potential passive immunization therapeutic
agents (117).
Apart from macaques, two human clinical trials have also determined that VRC01
passive transfusion is a safe and effective endeavor (118, 119). Passive immunization using
VRC01 is now being tested on a larger scale by HIV Vaccine Trials Network (HVTN) and
HIV Prevention Trials Network (Antibody Mediated Prevention) and involves 2700 highrisk homosexual men in the Americas (NCT02716675) and 1,900 heterosexual women in
Africa (NCT02568215). Participants will be intravenously administered with either 10
mg/kg or 30 mg/kg of VRC01 once every week for 8 weeks. A protective titer for passive
immunization will be determined by comparing number of infections in the dose groups
and a protective efficacy will be determined by comparing number of infections in VRC01
groups to placebo (120). Another CD4-binding bNAb, 3BNC117, was tested in a dose
escalation phase 1 clinical trial (NCT02018510) involving uninfected and HIV-1-infected
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individuals (113). A single 30mg/kg administration of 3BNC117 was shown to reduce
viremia by 0.8-2.5 log10 and demonstrated favorable pharmacokinetics; however,
emergence of resistant viral strains was evident in some cases (113). In another small-scale
clinical trial (NCT02511990), 33 subjects received a single intravenous infusion of 101074 bNAb, which was well tolerated with a half-life of 25 days in uninfected and 12.8
days in HIV-1-infected individuals (121). Of the 13 HIV-1-infected patients enrolled in the
study, 11 participants showed a rapid decline and subsequent control of viremia (121).
Currently, the pharmacokinetics and anti-viral activity of PGDM1400 and PGT121 is
under investigation in HIV-infected and HIV-uninfected adults in a Phase I clinical trial
(NCT03205917).
Treatment regimens for passive immunization still require optimization. They can
differ based on pharmacodynamics and pharmacokinetics in serum, as well as the bNAbs
HIV-specific pharmacodynamic properties, such as neutralization efficacy, susceptibility
to viral resistance, and its capacity to mediate viral and antigen trafficking, processing, and
presentation. Regimens can also depend on the patient’s viral load, variants present at the
time of therapeutic administration, as well as their sensitivity to specific bNAbs (122).
Collectively, these factors will provide a more personalized regimen that will ensure viral
load suppression, with reduced susceptibility for viral evasion, as long as adherence is
maintained.
Although passive immunization shows promise, many factors contribute to raise
feasibility concerns for its application as a large-scale human prophylactic and therapeutic.
First, passive immunization involves high doses of antibodies over a long period of time.
Consequently, it requires relatively large amounts of expensive reagents, inflating the cost
to treat one patient. Additionally, monoclonal antibodies are difficult to produce in large
amounts. Therefore, passive immunization is currently limited by the absence of a costeffective and high yield monoclonal antibody production processes (38). Lastly, immunity
conferred by passive immunization is not long-lived and would require frequent and
regular re-administration depending on the relatively short half-life of antibodies (123).
This can lead to a potential adherence problem as seen with currently employed ART
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treatment. Taking a “therapeutic holiday” can theoretically allow escape variants to
develop, making subsequent treatment with the same antibody ineffective.

1.3.3

Gene transfer therapy
To overcome barriers associated with passive immunization, using gene transfer

technology to provide hosts with an anti-HIV bNAb gene is now becoming a very attractive
strategy. Previously successful gene replacement therapies have all used viral vectors for
gene delivery, since viruses are highly adapted for gene delivery to their host cells. These
have either involved direct viral vector injection to target tissues, or modification of cells
in culture by viral vectors, followed by cell expansion and injection. After injection, the
antibody gene in the transduced target cell can direct endogenous expression of the
antibody molecule and serve as a depot to synthesize bNAbs that are distributed to the
circulatory system. The host is now armed with a potent bNAb against HIV-1 that bypasses
the adaptive immune system (38).
A promising novel gene replacement methodology, vectored immunoprophylaxis
(VIP), is capable of in vivo bNAb gene delivery by a single injection of adeno-associated
virus vectors (AAV) vector. To evaluate and validate its plausibility, several animal model
studies have been conducted. Interestingly, an injection with AAV8 vector, encoding a full
length bNAb gene for either b12, 2G12, 4E10, 2F5, or VRC01, was demonstrated to
achieve peak antibody production in serum by 6 weeks, followed by a decrease that was
maintained at a consistent level for the remainder of the study. The immunodeficient mice
were then injected with human-derived PBMC for 2 weeks and were subsequently
challenged with 10ng of NL4-3 HIV-1 strain intravenously. A VRC01 titer of 8.3μg/ml
was able to provide complete protection against the HIV-1 challenge, thus demonstrating
a proof of concept of VIP (124). However, the intravenous HIV injection model is not
entirely transitive to human infection, which often occurs through the mucosal route.
Therefore, to model HIV human infection, a bone marrow-liver-thymic (BLT) chimeric
mouse model was intravaginally challenged with a low dose of HIV-1 JR-CSF strain. BLT
mice that were given VIP to express VRC01 were highly resistant to this challenge,
elucidating the successful VIP-mediated delivery of bNAb and its efficacy of protection
against HIV-1 (125). Efficacy evaluation at the primate level has also been carried out by
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SIV challenge of macaque monkeys, in which VIP-mediated bNAb expression was
detected for over 6 years, providing protection against infection (79).
Encouraging results in animal models has rallied substantial interest to push VIP
gene transfer therapy to clinical trials. However, before the onset of such trials, several
challenges associated with gene transfer therapy must be addressed. As previously
mentioned, anti-HIV bNAbs undergo high levels of somatic hypermutation. Such highly
mutated regions serve as potential targets for anti-idiotypic responses, which in turn would
diminish their protective activity and lead to the eventual loss of transgene expression (79).
Additionally, some bNAbs have a polyreactive characteristic, which allows them to bind
to human antigens with high affinity as well (126, 127). The autoreactive potential of such
bNAbs have been demonstrated using autoimmune diagnosing assays and testing on arrays
of human proteins. For example, VRC01, VRC02, CH106, and CH103 can bind to human
ubiquitin ligase E3A with high affinity, with avidity correlating to neutralization breadth
of the antibody (128). In studies involving the tracking of maturation from initial B cell
arrangement to breadth development, a correlation was observed between autoreactivity
and neutralization breadth (129). In addition, CH98, a CD4bs targeting bNAb, was isolated
from a person living with an HIV infection and systemic lupus erythematosus (SLE). When
testing the autreactivity of CH98, it was found to be capable of binding dsDNA, suggesting
that some bNAbs derive from an autoreactive pool of B cells (129). Autoreactivity may
pose a problem in gene transfer therapy, where an individual is endowed the ability to
endogenously and constitutively produce these bNAbs. A mechanism for controlling the
endogenous bNAb expression may alleviate some degree of autoimmunity concerns. This
leads to the unanswered question of how to achieve a protective bNAb level in transmission
sites while minimizing the side effects caused by long-term bNAb expression.

1.4 Rationale and hypothesis
The first historic “living drug”, genetically modified immune cells (CAR-T), has
been recently approved by the FDA. To address the aforementioned issues of achieving
controlled, long-term bNAb expression, we will develop another type of “living drug”, an
anti-HIV bNAb transduced controllable B cell for HIV prevention by modifying an antigen
specific class switched (IgM→IgG) B cell from influenza (Flu) immunized animals. We
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hypothesize that, based on memory response dynamics, the bNAb expression from the
transduced antigen-specific B cells can be modulated by the same immunogen in the
immunized animal. Specifically, after transfusion of the VRC01 transduced B cells back
to the Flu-vaccinated mouse, these primary B cells can be specifically activated by another
Flu immunization to produce anti-HIV bNAbs along with anti-HA (hemagglutinin)
antibodies. The advantage of this strategy is that the production of bNAbs is controllable,
as, in theory, HA-specific antibody-secreting short-lived plasma cells will die out if the
mouse does not receive further Flu vaccination. Alternatively, we are also developing an
HIV specific B cell model to modulate bNAb expression, by modifying B cells to express
both membrane-bound and soluble versions of a bNAb. In theory, the membrane-bound
version of the bNAb will serve as a B cell receptor (BCR), and upon stimulation with HIV1 envelope, will drive expression of the soluble bNAb.
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2

Materials and Methods

2.1 Mice
C57BL/6 mice have been previously described (130). Female C57BL/6 mice that
were 6-8 weeks old were purchased from Charles River Laboratories and housed at
Western University’s Health Sciences animal facility. All experiments were monitored and
performed in compliance with the Western University Council on Animal Care.

2.2 Cell lines
Adherent Platinum-E cells and NIH3T3 cells, kindly provided by Dr. Dekoter, were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Wisent Inc.) with 10%
Fetal Bovine Serum (FBS) (Wisent Inc.) at 37°C with 5% CO2. Anti-p24 hybridoma cells
were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
Anti-HIV-1 p24 Hybridoma (183-H12-5C) (Cat# 1513), and maintained in RPMI with
10% FBS, 100U of penicillin (Cellgro) and 100 g of streptomycin (Cellgro) per mL, and
1% L-glutamine (Wisent Inc.).

2.3 Construction of MIG-VRC01, MIG-MB-N6, MIG-SB-N6
and MIG-MB-SB-N6 retroviral vector
Genscript services were used to synthesize a 2.25Kbp DNA fragment, which
consisted of heavy chain (HC) and light chain (LC) of VRC01, separated by a 24-amino
acid 2A peptide of Foot-and-Mouth-Disease virus (FMDV). A furin cleavage site (RAKR)
was also incorporated between the C-terminus of the HC and N-terminus of the 2A peptide.
The full length VRC01 sequence was inserted into pMA plasmid and was flanked by BglII
and EcoRI restriction enzyme cut sites. Next, MIGR1 (MIG), a Murine Stem Cell Virus
(MSCV)-based retroviral vector (131) kindly provided by Dr. Dekoter, and pMA-VRC01
were subjected to a double digestion with BglII and EcoRI (Thermo Fisher Scientific) as
per the manufacturer’s instructions. The digested, linearized VRC01 and MIGR1 products
were purified with QIAquick Gel Extraction kit (Qiagen) and subsequently ligated with T4
DNA Ligase (NEB) to form MIG-VRC01.
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For the construction of MIG-MB-SB-N6, Genscript services were first used to
sequence anti-p24 antibody produced by anti-p24 hybridoma. The variable region
sequence of the anti-p24 antibody HC and LC were replaced with that of N6 to produce a
chimeric sequence consisting of the anti-p24 antibody backbone and the variable regions
of N6. Additionally, an IgG hinge and intracellular domain was added between C-terminus
of the HC and N-terminus of the furin cleavage site to produce membrane bound N6 (MBN6). On the other hand, vK- promoter and B-cell enhancer sequences were added prior to
the chimeric antibody sequence to produce soluble N6 (SB-N6). Next, Genscript services
were used to generate the 2.4Kbp MB-N6 and the 3.4Kbp SB-N6 constructs, which were
inserted into pUC57 plasmid. Both MIGR1 and pUC57-MB-N6 were digested with BglII
and HpaI (Thermo Fisher Scientific) as per manufacturer’s instructions, their products were
purified with QIAquick Gel Extraction kit, and ligated to form MIG-MB-N6. Then, MIGMB-N6 and pUC57-SB-N6 were digested with MluI and HpaI (Thermo Fisher Scientific),
their products were purified, and ligated with T4 DNA Ligase (NEB) to form MIG-MBSB-N6. Next, to generate MIG-SB-N6, MIG-MB-SB-N6 was digested with BglII and HpaI
(Thermo Fisher Scientific) to remove MB-N6. Fragments were purified with QIAquick
Gel Extraction kit (Qiagen), and the correct fragment was re-ligated using T4 DNA Ligase
to produce MIG-SB-N6.
Transfection quality plasmid DNA was prepared by transformation and growth in
MIG-VRC01 into E. Coli ElectroMAX STBL4 bacteria (Thermo Fisher Scientific) and
purified using Qiagen plasmid Maxiprep kit (Qiagen). MIG-VRC01 construct was verified
by triple digestion with BglII, EcoRI, and PvuI (Thermo Fisher Scientific). MIG-MB-N6
and MIG-MB-SB-N6 constructs was verified by double digestion with BglII and HpaI, and
MluI and HpaI (Thermo Fisher Scientific), respectively. Products were visualized on 1%
agarose gel and resultant bands were compared to pUC57 or pMA-based parent construct
and MIGR1 vector maps.

2.4 Generation of pseudotyped retroviruses
MIG-VRC01, MIG-MB-N6, and MIG-MB-SB-N6 pseudotyped retrovirus
particles were generated by transient transfection using FuGENE6 Transfection reagent
(Promega) according to the manufacturer’s protocol. Briefly, 4x105 Platinum-E (Plate-E)
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retroviral packaging cells (kindly provided by Dr. Rodney DeKoter) were plated in each
well of 6-well plate 24 hours prior to transfection to obtain the desired confluency of 6080%. The vector of interest was co-transfected with pCL-Eco (Addgene, Plasmid #12371)
to increase viral yield (132). Each well was transfected with an optimized 3:1 ratio of the
vector of interest to pCL-Eco, with the total plasmid DNA being 3 μg, and 6 μL FuGENE6.
The Plat-E cells were cultured under standard conditions in DMEM with 10% Fetal Bovine
Serum (FBS). Successfully transfected cells produced GFP, and thus, transfection
efficiencies were determined using fluorescent microscopy and flow cytometry.
Transfection supernatants were collected 48 hours post-transfection and stored at -80C
until use.

2.5 Splenocyte isolation, and B cell enrichment and
stimulation
To isolate splenocytes, 6-8week old mice were euthanized and their spleen were
harvested. A PYREX® Tenbroeck tissue grinder (Thermo Fisher Scientific) was used to
homogenize the spleen, and the homogenized tissue was poured through a 70μm cell
strainer (Sigma-Aldrich) to get a uniform single-cell suspension. The splenocytes were
then centrifuged at 1500rpm for 6 minutes, and resuspended and incubated for 3 minutes
at room temperature in 10μL Ammonium-Chloride-Potassium (ACK) red blood cell lysis
buffer to remove the red blood cells from white blood cells. Splenocytes were then washed
twice with 10mL Fluorescence-Activated Cell Sorting (FACS) buffer (2mM EDTA
(Sigma), 0.5% BSA (Sigma) in PBS (Wisent Inc.)).
To specifically isolate B cells from the splenocytes, B cell enrichment was
performed by negative selection using biotin-conjugated CD43 (S7) antibody (BD
Biosciences), streptavidin microbeads (Miltenyi Biotec), and LD depletion columns and a
VarioMACS separation unit (Miltenyi Biotec). The splenocytes were run through the LD
column on a VarioMACS separation unit where labelled CD43 positive cells were retained
and CD43 negative cells (i.e. B cells) were collected in flow-through. B cells were enriched
based on manufacturer’s protocol. Briefly, 5x107 splenocytes were labelled with 0.5ug
biotin-conjugated anti-CD43 antibody and 10uL streptavidin microbeads and applied to an
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LD column. B cells in the flow-through were counted using a hemocytometer and 107 B
cells were plated per well in a 6 well plate.
Depending on the experiment, 107 B cells were plated per well in a 6 well plate,
cultured in complete RPMI1640 and stimulated for 24 hours, 48 hours, or 72 hours with
one of the following conditions prior to transduction: (1) 10 ng/mL interleukin-4 (IL-4)
(Sigma) and 10 ng/mL interleukin-5 (IL-5) (Sigma), (2) IL-4, IL-5 and 100 ng/mL CD40
ligand (CD40L) (Sigma), (3) IL-4, IL-5 and 5 μg/mL lipopolysaccharide (LPS) (Thermo
Fisher Scientific), (4) LPS alone, (5) 5 μg/mL HIV-1 IIB p24 recombinant protein (NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat# 12028) (6) 5 μg/mL, 1.67
μg/mL, 0.56 μg/mL, 0.18 μg/mL, or 0.067 μg/mL of pooled HA (Sino Biological) from
four

Influenza

H1N1

strains:

B/Phuket/3073/2013

(Cat#

40498-V08B),

A/California/04/2009 (Cat# 11055-V08H4), A/Michigan/45/2015 (Cat# 40567-H08H),
B/Brisbane/60/2008 (Cat# 40016-V08B).

2.6 Transduction of cells
Transduction of stimulated primary B cells, and NIH3T3 and anti-p24 hybridoma
cells were carried out by spinoculation. Briefly, 106 cells were pelleted and resuspended in
2mL of MIG-VRC01, MIG-SB-N6, MIG-MB-N6, or MIG-MB-SB-N6 transfection
supernatant. Cells were then centrifuged for 2 hours at 800 xg and 30C in the presence of
4μg/mL polybrene (Sigma). Following spinoculation, cells were resuspended in complete
RPMI1640 media and transferred to 6 well plates where they were cultured for 48 hours.
Transduction efficiencies were determined by quantifying GFP-expressing B cells using
flow cytometry.

2.7 Flow cytometry analysis and cell sorting
For detection of HA-specific B cells, Lightning-Link ® APC Antibody Labelling
kit was used to conjugate pooled HA with APC as per manufacturer’s protocol. Cells were
stained with APC-conjugated HA (1:100) in FACS buffer for 20 minutes at room
temperature and with Zombie AquaTM (BioLegend) according to manufacturer’s protocol.
The stained cells were then fixed with 4% PFA. For cell surface detection of MB-N6,
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Lightening-Link ® PE antibody Labelling kit (Novus Biologicals) was used to conjugate
gp140 B.6240 (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat# 12572)
with PE. Cells were stained with PE-conjugated gp140 (1:100) in FACS buffer for 20
minutes at room temperature and with Zombie Aqua (1:1000). The stained cells were then
fixed with 4% PFA (Electron Microscopy Science). For intracellular detection of MB-N6,
cells were first stained with Zombie Aqua, fixed with 4%PFA, permeabilized with 500uL
of 0.1M Triton x100 (Sigma-Aldrich) at room temperature for 15 minutes, and then stained
with PE-conjugated gp140. Antibody-stained cell analysis and sorting were performed
using the FACSCanto and FACSAriaIII systems, respectively (BD Biosciences). Sorted
cells were determined to be of >98% purity.

2.8 Mice immunizations and adoptive transfer of B cells
All immunizations were performed using the 2018/2019 seasonal quadrivalent Flu
vaccine (Fluzone, Sanofi Pasteur). Intramuscular (IM) immunizations were administered
with 9μg of the Flu vaccine in the thigh muscles; whereas, intraperitoneal (IP)
immunizations were administered with 24μg of the Flu vaccine. Adoptive transfer of B
cells was done through intravenous injection of the cells suspended in PBS. Blood draws
were performed via tail-vein bleed.

2.9 Detection of antibodies using Enzyme-Linked
Immunosorbent Assay (ELISA)
To detect VRC01, anti-p24, or SB-N6 antibody concentrations from culture
supernatants or mouse sera, a sandwich ELISA was performed using medium-binding
capacity ELISA plates (Greiner Bio-One). Plates were coated with 50ng/well of HIV-1 IIB
p24 recombinant protein or HIV-1 gp140 B.6240 recombinant protein in PBS. Antigencoated plates were incubated overnight at 4°C, following which the plates were washed 5x
with wash buffer (0.05% Tween-20 in PBS) and subsequently blocked with 200uL of
blocking buffer (10%FBS, 0.05% Tween-20 in PBS) per well for 1 hour at 37°C. Plates
were washed, and standards and sample dilutions were prepared using blocking buffer and
were applied at 50uL per well in duplicates or triplicates. For detection of VRC01, NIHderived VRC01 (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat#
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12033) was used as the standard. For detection of SB-N6, NIH-derived N6 (NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH: Cat# 12968) was used as the standard
unless stated otherwise. Samples and standards were incubated at 37°C for 1 hour.
Unbound antibodies were removed by washing with wash buffer. Next, 50μL of Goat antimouse or anti-human horseradish peroxidase (HRP) (Sigma) coupled secondary antibodies
were used at a concentration of 1μ/mL in blocking buffer for the detection of VRC01, N6,
SB-N6 and anti-p24 antibodies, respectively. Assay was developed using 50 μL/well of
SureBlue TMB 1-component microwell peroxidase substrate (SeraCare), and the reaction
was stopped after 5 minutes with 50 μL of 0.1 N H2SO4 to each well. Optical densities
(OD) were measured using the Cytation5 imaging reader (BioTek) at 450 nm using Gen5
software, and standard curves were generated to determine antibody concentrations.

3

Results

3.1 Modulation of bNAb expression from HA-specific B cells
with Flu vaccine
3.1.1

MIG-VRC01 transduced anti-HIV-1 p24 hybridoma cells can
simultaneously produce VRC01 and anti-p24 antibody
To overcome limitations associated with passive immunization and gene transfer

therapy, we proposed a model in which bNAb (e.g. VRC01) expression can be controlled
with the Flu vaccine by targeting bNAb-transduced HA-specific B cells for activation. Our
first objective was to generate a retroviral vector (MIGR1) capable of expressing VRC01
(MIG-VRC01).
First, a VRC01 DNA fragment was synthesized to contain a FMDV 2A peptide
between the heavy chain (HC) and light chain (LC). The FMDV 2A peptide undergoes
self-cleavage, resulting in a 1:1 ratio of HC and LC, allowing for a more efficient
expression of VRC01 (133). The designed VRC01 construct was then inserted into the
MSCV-based retroviral vector, MIGR1 (Fig. 3A).
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Since MIG-VRC01 transduced HA-specific B cells would be required to express
both VRC01 and anti-HA antibodies, evaluating the production of two antibodies from
antibody producing cells was crucial.

To test the co-expression of two dissimilar

antibodies, as a model system, we used an anti-p24 hybridoma cell line that produces
monoclonal IgG against HIV-1 p24, and transduced these cells with MIG-VRC01.
Following transduction, six GFP+ stably-transduced anti-p24 hybridoma clones were
generated using limiting dilution (Fig. 3B). These clones were grown to confluency and
their supernatants were collected and subjected to an ELISA to detect and compare levels
of anti-p24 and VRC01 antibody production. Construction of a standard curve based on
the OD450 of serially diluted anti-p24 and VRC01 mAb allowed for quantification of antip24 antibody and VRC01, respectively (Fig. 3C-D). Anti-p24 antibodies were a 100-fold
greater in concentration than VRC01 in cell culture supernatants of the stably-transduced
hybridoma clones (Fig. 3E). While p24 antibody levels ranged from 1-5 µg/mL, VRC01
antibody levels were detected at 10-50 ng/mL (Fig. 3E). Although production of anti-p24
antibody was significantly higher than that of VRC01, the p24 hybridomas transduced with
MIG-VRC01 served as a proof-of-concept for the simultaneous production of two different
antibodies in the same B cell.
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Figure 3. Anti-p24 hybridoma cell clones stably transduced with MIG-VRC01
pseudotyped retroviruses produced anti-p24 and VRC01 antibodies simultaneously.
(A) Diagram of the gene cassette used to express VRC01 from the MIGR1 vector. Antip24 hybridoma cells were first transduced with 2mL of MIG-VRC01 pseudoviruses
through pseudoviruses at 800xg for 2 hours at 30 ºC in the presence of 4 µg/mL Polybrene.
The cells were then serially diluted and plated in 96-well plates to screen for stablytransduced single cell clones by detecting GFP expression using fluorescence microscopy.
(B) Six GFP-positive cell clones were identified and expanded into individual monoclonal
populations of transduced hybridoma cells. Cell culture supernatants were collected from
each of the six stably-transduced hybridoma cell clones. Medium-binding ELISA plates
were coated with either HIV-1 p24 recombinant protein or HIV-1 gp140 recombinant
protein to detect p24 and VRC01 antibodies, respectively. Anti-mouse or anti-human IgG
HRP secondary antibody were used for p24 or VRC01 antibody detection, respectively.
Plates were read at 450 nm on a microplate reader. Standard curves were constructed for
(C) p24 antibody and (D) VRC01 antibody. Data points are presented as mean of OD450
readings, corrected according to OD450 from media-only negative control wells. (E)
Comparison of p24 and VRC01 antibody levels found in cell culture supernatant of stablytransduced hybridoma clones. p24 and VRC01 antibody concentrations were calculated
based on their respective standard curves and presented as the mean +/- SEM. All samples
were conducted in triplicates (n=1).
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The efficient co-expression of two antibodies requires accurate pairing of two
distinct heavy and light chain units. Several undesirable by-products can be formed in the
production process, including heavy chain recombination of the two different antibodies
and non-cognate light chain pairings (134). To assess whether random chain pairing is the
underlying cause of low VRC01 production compared to p24 antibody, cell culture
supernatant was collected following a 48-hour incubation from p24 hybridoma cells before
and after transduction with MIG-VRC01. The cell culture supernatants were serially
diluted and subjected to an ELISA to compare p24 antibody production with and without
VRC01 (Fig. 4). The OD450 measurements of the serially diluted p24 hybridoma
supernatant before and after transduction closely resembled each other, indicating similar
p24 antibody concentrations in both conditions (Fig. 4). If random chain pairing was a
major factor here, p24 antibody levels would exist at higher concentrations in the pretransduced hybridoma supernatant. Collectively, this suggests that the low VRC01
production may not be due to chain pairing issues.
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Figure 4. Anti-p24 antibody produced by p24 hybridoma cells before and after
transduction with MIG-VRC01 pseudotyped retroviruses.
Non-transduced anti-p24 hybridoma cells and a stably-transduced VRC01 expressing
clone were cultured in a 6-well plate for 48 hours. Cell culture supernatants were collected,
serially diluted, and subjected to an ELISA coated with HIV-1 p24 recombinant protein to
capture p24 antibodies. Anti-mouse IgG HRP secondary antibody was used for p24
antibody detection and plates were read at 450nm on a microplate reader. Data points are
presented as mean of OD450 readings, corrected according to OD450 from medium-only
negative control wells. All samples were plated in duplicates. Data were obtained from one
independent experiment (n=1).
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3.1.2

LPS stimulation results in the highest transduction efficiency
with MIG-VRC01 pseudotyped retrovirus
MIGR1-based transduction of primary B cells has been reported to be difficult, with

low transduction efficiencies of 8-15% (135). For our purposes, the number of VRC01
expressing HA-specific B cells would determine the initial population of Flu-targetable
cells that can be controlled for VRC01 expression. Therefore, we next sought to optimize
conditions that would yield a sufficiently high primary B cell transduction efficiency. To
do so, the spleen from C57BL/6 mice was harvested, and B cells were enriched using
negative selection for CD43-negative cells with anti-CD43-biotin and streptavidin. Since
retrovirus transduction requires mitotically active cells, the enriched B cells were cultured
for 24, 48, or 72 hours in complete RPMI1640 media containing one of the following
conditions: (1) IL-4 and IL-5, (2) IL-4, IL-5 and CD40L, (3) IL-4, IL-5 and LPS, or (4)
LPS only. Subsequently the B cells were transduced via spinoculation to determine the
optimal stimulation condition for transduction. Enriched B cells were also stimulated with
LPS for 24, 48, or 72 hours, but were not transduced and instead cultured with complete
RPMI to serve as a control. Flow cytometry was performed 48 hours post-transduction to
quantify percentage of GFP-positive cells as a measure of transduction efficiency. Of the
durations tested, stimulation for 48 hours yielded a peak transduction efficiency for all
conditions (Fig. 5A). More specifically, stimulation with LPS for 48 hours prior to
transduction resulted in the highest transduction efficiency of 41.3% (Fig. 5A). IL-4/IL5/CD40L stimulation of B cells for 48 hours resulted in the second highest transduction
efficiency of 37%, followed by stimulation with IL-4/IL-5/LPS at 29.4%. It has previously
been shown that IL-4/IL-5 are associated with B cell survival and to a lesser extent,
stimulation (136, 137). As such, IL-4/IL-5 stimulation resulted in the lowest transduction
efficiency at 9.72% successfully transduced cells (Fig. 5A). Cell viability was greater than
90% for all the conditions, with similar viabilities between non-transduced and transduced
cell populations, indicating that our spinoculation method and the virus were not harmful
towards the cells (Fig. 5B).
The MIG-VRC01 vector was then evaluated to determine if they produce VRC01
from primary B cells. Cell culture supernatants of the transduced primary B cells were
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collected 48 hours post-transduction and subjected to an antigen-specific ELISA. Only the
supernatants of cells that were stimulated for 48 hours pre-transduction were collected,
with non-transduced cells serving as a control (Fig. 5C). Expression of VRC01 was evident
in the undiluted supernatants as seen by the presence of positive signals. Moreover, the
signals were undetectable at 1:10 dilution of the supernatants, suggesting low antibody
titres (Fig. 5C).
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Figure 5. MIG-VRC01 pseudovirus transduction efficiency in murine primary B
cells following cell stimulation.
(A) GFP as a measure of transduction efficiency of B cells stimulated with various
conditions. (B) Cell viability of the transduced B cells determined by using propidium
iodide staining. Enriched B cells were stimulated with IL-4 (10 ng/mL), IL-5 (10 ng/mL),
CD40L (100 ng/mL) or LPS (5 µg/mL) in the indicated conditions for 24, 48, or 72 hours.
Following stimulation, 1x106 B cells from each condition were spinoculated with 2 mL
MIG-VRC01 pseudoviruses at 800 x g for 2 hours at 30 ºC in the presence of 4 µg/mL
Polybrene. Non-transduced control cells were stimulated with LPS for 24, 48, or 72 hours,
then cultured in fresh complete RPMI1640 media for 48 hours. 2x105 cells were collected
48 hours post-infection and analyzed by flow cytometry for GFP expression as a measure
of transduction efficiency and cell viability using propidium iodide staining (A-B). (C)
VRC01 expression from supernatants of transduced B cells pre-stimulated for 48 hours
with the indicated conditions. Cell culture supernatants were collected 48 hours posttransduction, diluted to the indicated ratios, and subjected to a standard ELISA run. ELISA
plates were coated with HIV-1 gp140 recombinant protein, and expression of VRC01 from
the culture supernatant was detected using anti-human IgG HRP secondary antibody. Plates
were read at 450 nm, and the average OD450 was calculated and plotted. All samples were
conducted in duplicates (n=1).
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3.1.3

Flu vaccination schedule produced a modest HA-specific B
cell population
Since our strategy relies on the transduction of HA-specific B cells, we sought to

determine the number of HA-specific B cells that can be isolated, for subsequent
transduction with MIG-VRC01, from C57BL/6 mice following our flu immunization
schedule (Fig. 6A). To do this, nine 6-8-week-old mice were immunized twice with the
2018/2019 seasonal quadrivalent Flu vaccine at a 3-week interval. Two weeks following
the second immunization, spleens were harvested, and B cells were enriched by negative
selection for CD43-negative cells using anti-CD43-biotin and streptavidin. The enriched B
cells were then stained with APC-tagged HA to detect anti-HA B cells by flow cytometry,
with unstained B cells serving as a control; the gating strategy is shown in Figure 6B. Using
our vaccination schedule, we found that 1.7% of the B cells were HA-specific (Fig. 6C).
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Figure 6. HA-specific B cell population from spleen of C57BL/6 mice following our
Flu vaccination schedule.
(A) Our vaccine schedule to generate a HA-specific B cell population. Eight mice were
immunized with 9 ug of HA from the 2018/2019 seasonal quadrivalent Flu vaccine via
intramuscular route. Three weeks post initial vaccination, a booster was administered of
the same dose, also through the intramuscular route. Splenocytes were isolated 2-weeks
post booster vaccination, and B cells were enriched and pooled together. The enriched B
cells were stained with APC-tagged HA to detect HA-specific B cells and dead cells were
excluded by staining with Zombie Aqua. (B) Flow cytometry analysis was performed by
gating out dead cells, applying a tighter gate on live cells using forward and side scatter,
and gating for singlets. (C) HA-specific B cell population was analyzed within the singlet
gate and compared to the unstained control. Data were analyzed using FlowJo-10.4. Data
were obtained from one independent experiment (n=1).
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In addition, 1.5x106 HA-specific B cells and 30x106 non-HA-specific B cells were
sorted using APC-tagged HA. These two cell populations were first stimulated with LPS
for 48 hours followed by transduction with MIG-VRC01. Strikingly, following the 48
hours stimulation with LPS, a combined cell survival of 9.7% was observed. Although LPS
is a known potent, non-specific, stimulator of B cells leading to proliferation and survival,
cell sorting is known to cause cell stress, perturbation, and even injury to the sorted cells
(138). Therefore, cell sorting is a potential cause of the reduced number of live cells.

3.1.4

Maximizing the number of HA-specific B cells for adoptive
transfer
Taking into account the low recovery of B cells after sorting, we proposed two

possible approaches to maximize the number of MIG-VRC01 transduced B cells that can
be used for adoptive transfer: 1) increase the population of HA-specific B cells from
immunized mice 2) avoid cell sorting.
To increase the HA-specific B cell population, we hypothesized that Flu vaccine
administration via the intraperitoneal (IP) route 24 hours prior to HA-specific B cell
isolation would result in a greater HA-specific B cell population. IP immunizations drain
mainly into the spleen, the tissue we use to isolate HA-specific B cells. Therefore, in theory,
the IP immunization would serve as an in vivo stimulation of the HA-specific B cells in the
spleen, leading to their activation and proliferation. To test this, two were immunized twice
with the 2018/2019 seasonal quadrivalent Flu vaccine at a 3-week interval (Fig. 7A). Two
weeks following the booster shot, a mouse was immunized via the IP route with another
dose of the Flu vaccine 24 hours prior to B cell enrichment and the subsequent HA-specific
B cell population quantification using flow cytometry (Fig. 7A). B cells from the mouse
that did not receive the IP Flu immunization was used as a control. Mouse that received an
IP Flu immunization had an HA-specific B cell population of 5.1%, which is 3-fold greater
than that of non-IP immunized mice (Fig. 7B). Although no conclusions can be drawn due
to low number of replicates, a trend is seen in which IP immunization 24 hours prior to B
cell enrichment induces a greater HA-specific B cell population compared to non-IP
immunized control (Fig. 7B).
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Figure 7. Intraperitoneal immunization with Flu vaccine 24 hours prior to B cell
enrichment increases population of HA-specific B cells.
Two mice were immunized twice at 3-week intervals with 9ug of HA from the 2018/2019
seasonal quadrivalent Flu vaccine via intramuscular route. (A) A mouse either received or
did not receive another Flu vaccine via intraperitoneal route 24 hours prior to B cells
enrichment. (B) The enriched B cells were stained with APC-tagged HA to determine HAspecific B cell population from the two vaccine strategies and dead cells were excluded by
staining with Zombie Aqua. Flow cytometry analysis was performed by gating out dead
cells, applying a tighter gate on live cells using forward and side scatter, and gating for
singlets. HA-specific B cell population was analyzed within the singlet gate. Data were
analyzed using FlowJo-10.4. Data were obtained from one independent experiment (n=1).
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Cell sorting was initially intended for separating HA-specific B cells from non-HA
specific B cells, thus allowing the use of LPS, a potent but non-specific stimulator.
However, if we are to avoid cell sorting to increase cell viability, a more targeted approach
would have to be applied to specifically stimulate HA-specific B cells from the pool of
enriched B cells (ie. through stimulation by HA). This would allow for a more focused
transduction of HA-specific B cells with MIG-VRC01, ensuring the intended modulatory
effect that will be tested is via HA-specific B cell activation.
To test whether HA-specific B cells can be stimulated by purified HA protein in
vitro, B cells were enriched from mice that received three Flu immunizations; two
immunizations at 3-week intervals and another immunization 24 hour prior to B cell
isolation. 10x106 enriched B cells were then stimulated with a 3-fold gradient of HA
concentrations ranging from 5ug/mL to 0.062ug/mL. B cells were also stimulated with LPS
at 5ug/mL, p24 at 5 ug/mL, or media; the latter two serving as a non-specific stimulation
and no stimulation negative controls, respectively. The number of live cells were quantified
at 24- and 48-hours post-stimulation. With increasing concentrations of HA, an increase in
the number of live cells was observed at both 24 hours and 48 hours post-stimulation (Fig.
8A). LPS and HA stimulation at 5ug/mL resulted in the highest number of live cells post
48 hours with similar cell counts in the two conditions (Fig. 8A). Next, cells from each
stimulation condition were transduced with MIG-VRC01 pseudovirus by spinoculation.
Flow cytometry was used to determine whether the number of live cells observed from
each stimulation condition coincides with transduction efficiency of HA-specific B cells.
Strikingly, although LPS and HA stimulation at 5ug/mL resulted in a comparable live cell
count, LPS stimulation resulted in a 4-fold greater transduction efficiency of HA-specific
B cells (Figure 8B). This suggests that the high number of live cells observed with 5ug/mL
of HA stimulation may be due to increased cell survival instead of proliferation.
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Figure 8. Stimulation of enriched B cells with various concentrations of HA proteins
followed by transduction with MIG-VRC01.
Mice were immunized twice at 3-week intervals with 9ug of HA from the 2018/2019
seasonal quadrivalent Flu vaccine via intramuscular route. Mice were again immunized
with the Flu vaccine via intraperitoneal route 24 hour prior to B cells enrichment. Enriched
B cells were then cultured for 48 hours with HA concentrations ranging from 5ug/ml to
0.062ug/ml at 3-fold titrations. B cells were also treated with LPS (5ug/ml), HIV-1 p24
(5ug/ml), or were left unstimulated. (A) Number of live cells were quantified 24 hour and
48 hours post-treatment by staining cells with trypan blue and counting cells individually
using a hemocytometer (n = 2). (B) Cells from each condition were then transduced with
2mL of MIG-VRC01 pseudoviruses through spinoculation at 800xg for 2 hours at 30 ºC in
the presence of 4 µg/mL Polybrene. The cells were then cultured for 48 hours and then
stained with APC-tagged HA and Zombie Aqua. Flow cytometry was used to determine
transduction efficiency (based on GFP expression) of HA-specific B cells from each
condition. Flow cytometry analysis was performed by gating out dead cells using Zombie
Aqua, applying a tighter gate on live cells using forward and side scatter, and gating for
singlets and GFP-positive cells. HA-specific B cell transduction was analyzed within the
GFP-positive gate. Data were analyzed using FlowJo-10.4. Data were obtained from two
independent experiment (n=2).
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3.1.5

Preliminary in vivo study to test modulation of bNAb
expression by Flu vaccine
During the course of the study we were able to obtain the CD4bs-targeting N6

sequence. N6 is the most potent bNAb described thus far, and has one of the highest
neutralization breadths. It has been shown that N6 can neutralize many isolates that are
resistant to VRC01 and other CD4bs antibodies (79). Because of this increased potential
effectiveness, we chose to use N6 over VRC01 for future studies. To generate the soluble
N6 (SB-N6) sequence, anti-p24 antibody produced by murine anti-p24 hybridoma was
sequenced and used as the backbone (Appendix 1B). The variable region of the N6
antibody (both HC and LC) was used to replace that of the anti-p24 antibody while keeping
the remainder of the sequence the same (Appendix 1B). As with VRC01, the SB-N6
fragment was inserted into the MIGR1 vector to generate MIG-SB-N6.
To test whether bNAb expression from the transduced HA-specific B cells can be
modulated by the Flu vaccine in the immunized animal, mice were immunized twice with
the seasonal 2018/2019 quadrivalent Flu vaccine. Two weeks following the second
immunization, a third immunization was administered via the IP route, and spleens of the
mice were extracted post 24 hours and B cells were enriched. HA-specific B cells were
then sorted using APC-tagged HA. The HA-specific B cells were then stimulated with LPS
for 48 hours, transduced with MIG-SB-N6, and adoptively transferred into four immunized
mice (Fig. 9A). These mice were Flu immunized every 2-weeks, and their serum was
collected weekly for 7 weeks and subjected to an ELISA to detect SB-N6 levels (Fig. 9B).
After the first two immunizations, a slight increase was observed in the expression of SBN6 in all the mice tested (Fig. 9B). Interestingly, after the third immunization, a large
increase in the expression of SB-N6 was observed in two mice, followed by a gradual
decrease (Fig. 9B). To show survival and responsiveness of the infused B cells over a long
period of time, we are currently waiting for the SB-N6 response to fall below levels of
detection to allow for the B cell population to contract. We will then boost the mice again
with Flu immunization to test survival and responsiveness of the infused B cells over a
long period of time. Together, a modulatory effect is seen in SB-N6 expression from the
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immunized mice infused with SB-N6 expressing HA-specific B cells, where SB-N6
concentrations increase following Flu immunizations.

A

B
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Figure 9. Modulatory effect in SB-N6 production using Flu immunizations.
Donor mice were Flu-immunized intramuscularly twice at a 3-week interval, and again
intraperitoneally 24 hours before B cell enrichment. Using a cell sorter and APC-tagged
HA, HA-specific B cells were isolated, then stimulated with LPS for 48 hours, transduced
with MIG-SB-N6 pseudovirus, and subsequently infused into recipient mice (A).
Specifically, 3x104, 1.5x104, 1.5x104, and 1.1x104 MB-N6 expressing HA-specific B cells
were infused in mouse 665, 666, 667, and 672 respectively. Sera from the recipient mice
were collected 1 day post adoptive transfer and subsequently collected every 7 days. Sera
were serially diluted and were subjected to ELISA plates that were coated with HIV-1
gp140 recombinant protein to detect SB-N6 antibody concentrations (B). Intramuscular
Flu stimulations were administered to the recipient mice at the timepoints indicated by red
arrows. Standard curves were generated to allow for quantification of the SB-N6 antibody.
Sera subjected to ELISA were run as duplicates. Data were obtained from one independent
experiment (n=1).
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3.2 HIV-1 Env based modulation of bNAb expression from
an HIV-1 specific B cell model
3.2.1

SB-N6 is produced at high levels from MIG-MB-SB-N6
transduced anti-p24 hybridoma clone
As an alternative to the modulatory anti-HIV bNAb expressing B cells, we planned

to modify B-cells to express both membrane-bound (MB) and soluble (SB) N6 driven by
B cell promoter. In theory, the MB-N6 will serve as a B cell receptor (BCR) to bypass the
requirement of a Flu immunization for the stimulation of these MIG-MB-SB-N6
transduced B cells and can instead be activated with HIV-1 envelope protein. Stimulation
of these cells through MB-N6 will activate a B cell-specific promoter that will drive SBN6 expression (Appendix 2). Additionally, this strategy uses naïve B cells and circumvents
issues associated with cell survival after sorting HA-specific B cells. The combination of
HIV-1 specific activation of the bNAb response and use of a naïve B cell population allows
this strategy to play a more practical role in HIV-1 prevention and treatment.
The membrane-bound (MB-N6) and soluble N6 (SB-N6) sequences were designed
to avoid species-specific signal peptide recognition issues (Appendix 1A-B). A similar
approach to SB-N6 was used to design MB-N6, with the addition of a hinge sequence and
intracellular domain sequence (Appendix 1A-B). Immediately following the MB-N6 is a
B cell specific enhancer and vK- promoter, which will enable responsiveness to BCR
stimulation (Appendix 1C). The SB-N6 is downstream of the vK- promoter and under its
direct control for expression. MB-N6 and SB-N6 were inserted into the MIGR1 vector to
generate MIG-MB-SB-N6 (Appendix 1C).
To test the expression and functionality of SB-N6, anti-p24 hybridoma cells were
first transduced with MIG-MB-SB-N6. Following transduction, one GFP-positive stablytransduced anti-p24 hybridoma clone, 1-E-2, was successfully generated using limiting
dilution. 1-E-2 was grown to confluency and its supernatant was collected and subjected
to an ELISA to detect for the production of SB-N6 and compare its levels to that of antip24 antibody. Construction of a standard curve based on the OD450 value of serially diluted
anti-p24 or VRC01 mAb standards allowed for calculations of anti-p24 and SB-N6
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antibody concentrations found in the 1-E-2 culture supernatant (Fig 10A-B). VRC01 was
used as a representative standard for N6 since we were not in possession of N6 mAb at the
time (Fig. 10A). Anti-p24 antibodies were found at a 16-fold higher concentration in the
culture supernatant of 1-E-2 compared to SB-N6 (Fig. 10C). While p24 antibody
concentration in culture supernatant was 4.6µg/mL, SB-N6 antibody levels were detected
at 290 ng/mL (Fig. 10C). Next, the SB-N6 levels were also compared to VRC01
concentrations produced by MIG-VRC01 transduced anti-p24 hybridoma clones. On
average, the murine signal-peptide expressing SB-N6 antibodies were found at a 28-fold
greater concentration than the human signal-peptide expressing VRC01 (Figure 10D).
These results suggest that exchanging a foreign signal peptide for a species-specific signal
peptide, as well as the addition of a B cell-specific enhancer and promoter, can greatly
increase antibody expression.
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Figure 10. SB-N6 and VRC01 antibody production from stably-transduced anti-p24
hybridoma clones.
Anti-p24 hybridoma cells first transduced with 2mL of MIG-MB-SB-N6 pseudoviruses
through spinoculation at 800xg for 2 hours at 30 ºC in the presence of 4 µg/mL Polybrene.
The cells were then serially diluted and plated in 96-well plates to screen for stablytransduced single cell clones by detecting GFP expression using fluorescence microscopy.
One GFP-positive cell clone (1-E-2) was identified and expanded into individual a
monoclonal population of transduced hybridoma cells. Cell culture supernatants were
collected from 1-E-2 and subjected to ELISA plates that were coated with either HIV-1
p24 recombinant protein or HIV-1 gp140 recombinant protein to detect p24 or SB-N6
antibodies, respectively. Anti-mouse IgG HRP secondary antibody were used for antibody
detection and plates were read at 450 nm on a microplate reader. To determine
concentrations of SB-N6 and anti-p24 antibodies, standard curves were constructed for (A)
VRC01 antibody and (B) anti-p24 antibody. (C) Comparison of anti-p24 and SB-N6
antibody levels found in cell culture supernatant of 1-E-2. Anti-p24 and SB-N6 antibody
concentrations were calculated based on their respective standard curves (D) Comparison
of SB-N6 and VRC01 production by their respectively transduced anti-p24 hybridoma
clones. SB-N6 and VRC01 concentrations are presented as the mean +/- SEM Ab
expression by six VRC01-expressing clones and one SB-N6-expressing clone. All data
points are presented as mean of OD450 readings of duplicates, corrected according to OD450
from media-only negative control wells. Data were obtained from one independent
experiment (n=1).
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3.2.2

MB-N6 expression is detected intracellularly but not on the
cell membrane

In order for the MIG-MB-SB-N6 transduced cells to be activated with HIV-1 env,
MB-N6 must be expressed on cell surface and serve as a functional BCR. To determine
whether MB-N6 can be expressed on the cell membrane, anti-p24 hybridoma and NIH3T3
cells were transduced with MIG-MB-SB-N6. Following 48 hours, the cells were sorted
based on GFP expression to pool those that were successfully transduced. These cells were
cultured and subsequently stained with PE-tagged gp140 to detect cell surface expression
of MB-N6 by flow cytometry. When compared to the unstained control, it is evident that
MB-N6 is not expressed on the cell surface of the transduced p24 hybridoma and NIH3T3
cells (Fig. 11).
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Figure 11. Detection of MB-N6 expression from cells transduced with MIG-MB-SBN6 pseudovirus.
Expression of MB-N6 by (A) anti-p24 hybridoma and (B) NIH3T3 cells transduced with
MIG-MB-SB-N6. Anti-p24 hybridoma and NIH3T3 cells were transduced with MIG-MBSB-N6 pseudoviruses through spinoculation at 800xg for 2 hours at 30 ºC in the presence
of 4 µg/mL Polybrene. The cells were then sorted based on GFP expression to obtain
successfully transduced cell populations. The transduced cells were cultured and
subsequently stained with Zombie Aqua for cell viability and PE-tagged gp140 to detect
cell surface expression of MB-N6. Successfully transduced cells (GFP) that express N6
(PE-gp140) on their surface were quantified by gating out dead cells, applying a tighter
gate on live cells using forward and side scatter, and gating for singlets. Data was analyzed
using FlowJo-10.4. Data were obtained from one independent experiment (n=1).
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To determine why MB-N6 was not being expressed on cell surface, we sought to
detect MB-N6 production at the intracellular level. This would indicate whether the issue
is associated with protein production or export. To test this, NIH3T3 cells were transduced
with MIG-MB-N6, which was preferred over MIG-MB-SB-N6 for this experiment in order
to avoid confusion between intracellular expression of SB-N6 versus MB-N6. The
transduced cells were sorted based on GFP to pool a successfully transduced population of
the NIH3T3 cells. These cells were then either permeabilized to allow intracellular
detection of MB-N6 or left intact to measure cell membrane expression of MB-N6 with
PE-tagged gp140 by flow cytometry. Only 1.55% of the transduced NIH3T3 cells
expressed MB-N6 on the cell surface (Fig. 12A), whereas 98.3% were able to produce MBN6 intracellularly (Fig. 12B). This suggests that MB-N6 can be efficiently produced by the
transduced cells but cannot be expressed on the cell membrane.
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Figure 12. MB-N6 is produced at the intracellular level but not expressed on cell
membrane.
(A) Cell surface and (B) intracellular expression of MB-N6 in NIH3T3 cells transduced
with MIG-MB-N6. NIH3T3 cells were transduced with MIG-MB-N6 pseudoviruses
through spinoculation at 800xg for 2 hours at 30 ºC in the presence of 4 µg/mL Polybrene
and sorted based on GFP expression to obtain a successfully transduced cell population.
These cells were then cultured and either permeabilized with Triton X-100 or were left
intact. Staining with PE-tagged gp140 allowed for N6 detection and Zombie Aqua for
cell viability. Similar gating strategy was applied as in Fig. 9. Data was analyzed using
FlowJo-10.4. Data were obtained from one independent experiment (n=1).
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4

Discussion
This study explores a novel strategy of utilizing patient-derived anti-HIV bNAbs for

HIV prevention and therapeutic. By establishing a controllable bNAb expression system,
we will not only overcome hurdles associated with short-lived passive immunization
schemes, but also the adverse side effects caused by long-term bNAb expression. To
achieve this, our objective was to transduce HA-specific B cells with MIG-VRC01 or MIGSB-N6 pseudotyped retroviruses and evaluate the modulatory effect of subsequent Flu
immunizations on bNAb expression. In this preliminary study, we showed that following
infusion of SB-N6-expressing HA-specific B cells into recipient Flu-vaccinated mice,
subsequent Flu immunizations increased SB-N6 production.
MIGR1 vector, a Murine Stem Cell Virus (MSCV)-based retroviral vector, was
used in the construction of the MIG-VRC01 vector containing the VRC01 Ab gene.
MIGR1 can produce pseudo-retrovirus particles that contain gene of interest when
transfected into Platinum-E packaging cells (a packaging cell line expressing retroviral
Gag, Pol and Env proteins) (139). The vector has been previously shown to successfully
introduce and express target genes in various cell types, including pluripotent cell lines,
embryonic stem cells, and more specific to our interest, B- lymphoid cells (140, 141). The
MIGR1 vector uses the LTR promoter for expression of both heavy and light chains, which
are separated by a FMDV 2A peptide sequence. Additionally, successfully infected cells
express GFP under control of the IRES element which facilitates detection of transduced
cells (131).
Due to the non-dividing nature of most primary B cells, a stimulation condition that
induces optimal proliferation must be used for efficient gene delivery by our retroviral
transduction system (142). We explored the stimulatory effects of a combination of four
molecules: LPS, CD40L, IL-4, and IL-5. LPS is a potent mitogen of B cells with robust invitro proliferation responses through activation via TLR4 (143, 144). Although LPS is the
most commonly used mitogen for retrovirus-mediated gene transfer, we wanted to explore
a more direct route of B cell activation by exploiting the proliferative and clonal expansion
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effects of CD40L via cognate CD40-CD40L interaction. The IL-4 and IL-5 cytokines
provide additional signals for cell survival, differentiation, isotype switching, and antibody
secretion (136, 145). In line with literature (141, 146, 147), LPS stimulation resulted in the
most robust stimulation and subsequent transduction efficiency with MIG-VRC01,
followed by that with CD40L/IL-4/IL-5.
We were able to detect VRC01 antibody expression from transduced primary B
cells although the levels of the antibody produced were low. This could be the result of
various factors including low transduction efficiency or decreased cell viability.
Furthermore, genetic factors involving the expression vector, such as the equal expression
of LC and HC, the promoter and signal peptide sequence, can also play a role (148). Since
we achieved an optimized transduction efficiency of 41.3% with cell viability over 90%, it
is unlikely that these would be causes for low VRC01 expression. Additionally, we ensured
the 1:1 expression of HC and LC of VRC01 by inserting a FMDV 2A peptide between the
two chains. 2A elements have a self-cleavage property, therefore HC and LC would be
made from a single transcript (133). Upon translation, the 2A peptide would cleave itself,
ensuring an equal expression of HC and LC (133). It is well reported that although 2A
directs equivalent expression of both genes, it leaves a few amino acids at the C-terminal
region of the first gene (149–151). Therefore, we implemented a furin cleavage site
upstream of the 2A peptide to remove the extra amino acids.
Moreover, the MIGR1 LTR promoter has been shown to robustly express genes in
embryonic stem, carcinoma, and equally well in hematopoietic progenitors as well as their
differentiated descendent cells including B and T lymphocytes (152). Additionally, their
widespread use in transgene delivery to primary B cells suggests that the low expression
of VRC01 may not be due to strength of the MIGR1 LTR; however, we were unable to
achieve the reported robust expression. Another component to assess is the signal peptide
sequence, which guides the translocation of secreted proteins along the classical secretory
pathway. As the signal peptide of a nascent protein emerges from the ribosome, it binds to
the signal recognition particle (SRP), which consists of a well-conserved SRP54 protein,
among five others, and 7S RNA (153, 154). The binding of the signal peptide to the SRP
and the subsequent translocation of the complex to the ER is a known bottleneck in the
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secretory pathway of recombinant proteins (155). In our initial design of the MIG-VRC01,
the Ab contained its native, human, signal peptide. Several studies have shown that signal
peptides are extremely heterogenous yet functionally interchangeable even between
distinct species (155–157). Nonetheless, altering the signal peptide of a protein has been
shown to have a profound effect on protein production. A single amino acid substitution
from an optimal signal peptide has been shown to significantly reduce antibody expression
from CHO cells (155). Many studies have also discovered that the native signal peptide
may be suboptimal, and protein production can be improved by using signal peptides from
different species (155, 156, 158); however, evidence suggesting the opposite is also
extensive (155, 158). In support of the latter, we were also able to drastically increase
antibody production by replacing a human signal peptide with a species’-specific murine
signal peptide at the N-terminal of the HC and LC, in conjunction with the addition of a B
cell-specific promoter and enhancer. In addition, it has been postulated that different signal
peptides show varying affinities for the SRP which subsequently determines the efficiency
with which a nascent polypeptide chain enters the secretory pathway (155). It is likely that
having a species-specific signal peptide would enhance this interaction, thus increasing
antibody expression.
One of the objectives of our study was to demonstrate the co-expression of two
dissimilar antibodies from a single antibody-secreting cell. We found that although VRC01
and SB-N6 can be co-expressed with the innate antibody (anti-p24 antibody) of the
antibody-secreting cell (anti-p24 hybridoma), its production is drastically lower. When coexpressing two antibodies, chain pairing recombination can often occur, permitting the
production of unwanted, non-functional antibodies (134). Assuming random chain
association, a total of 24 = 16 combinations is possible from the two different light and
heavy chains (134). Of those, 6 are identical from a statistical association standpoint, which
leads to a 12.5% yield for correct antibody pairing (134). In our study, since the HC and
LC of VRC01 or SB-N6 were not linked via a linker sequence, it allows for such
recombination to occur. However, comparing anti-p24 antibody production from the p24
hybridoma cells before and after MIG-VRC01 transduction showed no difference in antip24 antibody production, suggesting that chain pairing may not be the limiting factor for
antibody production. It is equally likely that after transduction with MIG-VRC01, VRC01
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production was too low to have a major impact on anti-p24 antibody production. Further
experiments need to be carried out to determine the underlying cause of low transgene
antibody expression compared to that of the innate antibody.
Optimizing the number of HA-specific B cells is vital for our strategy of leveraging
HA-specific B cells to produce SB-N6 or VRC01. We found that an intraperitoneal (IP)
immunization 24hours prior to B cell enrichment resulted in a higher HA-specific B cell
population than the control. This is likely due to the IP immunization serving as an in vivo
stimulation condition, leading to activation and proliferation of HA-specific B cells. A
previous study showed that upon administration of ovalbumin (OVA) via the IP route, high
levels of OVA association to DCs and monocytes was detected, with peak association
observed at 6hours post immunization (159), which can lead to B cell activation. In
accordance with this finding, other studies have also used IP immunization 6hours prior to
antigen-specific B cell isolation and have successfully transduced them with MIGR1 (135).
The 6-hours noted in these previous experiments provides a timeline for the vaccine to
drain into the spleen and be processed by the monocytes and dendritic cells. For the
subsequent activation of the B cells, it is likely that more time will be needed. As such,
prior to our B cell isolation, an additional 18 hours was allocated for this process to occur.
To avoid cell sorting-related cell death, we used purified HA in an attempt to
specifically activate HA-specific B cells from a pool of enriched B cells. We found that
although there was a comparable increase in the number of live cells in the 5ug/mL HA
and LPS stimulation conditions, transduction efficiency of LPS stimulated cells was 4-fold
greater than that of HA stimulated cells. Since retroviral transduction requires both
activation and proliferation of cells (142), it is most likely that the observed increase in the
number of live cells in the 5ug/mL HA stimulation condition is due to increased cell
survival signaling through BCR but not proliferation. The distinction between B cell
survival and proliferation through BCR has been supported by a study where B cells that
possessed oncogenic mutations led to uncontrolled proliferation, but its survival was
dependent on the intrinsic tonic BCR signal (i.e. with no antigen present) (160). With
respect to extrinsic signaling, the crosslinking of the BCR on mature B cells with antigen
initiates signal cascades which lead to B cell survival and activation. However, there is a
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specific threshold which must be met for this signaling to occur (161). In our study, the
concentrations of HA used to stimulate the B cells may not be optimal to achieve the
activation threshold. As a result, while we may be achieving survival, we may not be
stimulating proliferation. Additionally, it has been demonstrated that stimulation with low
antigen concentrations do not enhance, but rather decrease cell viability when compared
with non-stimulated B cells (a phenomenon that we also observed in our study with
concentrations lower than 5ug/mL) (161). Importantly, the activation threshold of BCR
applies only when BCR alone is stimulated. The presence of a costimulatory signal such
as CD40 or cytokine receptors negates the requirement of the BCR activation threshold
(161). As such, in future attempts to stimulate HA-specific B cells in vitro, we will include
CD40L and IL-4 to mimic the costimulatory signals associated with T cell help.
In our preliminary in vivo study, we showed an anamnestic effect in SB-N6
expression from the immunized mice infused with SB-N6 expressing HA-specific B cells.
After subsequent stimulations with the Flu vaccine, an increase in serum SB-N6 was
observed. To our knowledge, it is the first study to show that antigen-specific B cells can
be leveraged to control the production of a transgenic antibody. We suspect that this is
likely through the standard antibody production process. The HA-specific BCR on these B
cells recognize the HA antigens and serve two roles in B cell activation. First, upon
receiving sufficient activation signal through its BCR, it transmits these signals directly to
the cell. Second, the BCR guides the intracellular uptake, the subsequent degradation and
presentation of the peptides on MHC II. The peptide:MHC II complex can be recognized
by antigen-specific helper T cells, generated through prior Flu vaccinations. This
interaction stimulates the helper T cells to produce cytokines that cause B cells to
proliferate and its progeny to differentiate into either antibody-secreting plasma cells,
memory B cells, or long-lived plasma cells (162). The activated plasma cells will increase
the activity of the B cell promoter to drive anti-HA antibody production, and since SB-N6
is also under the B cell promoter, it will simultaneously produce SB-N6.
To test the validity of our preliminary in vivo study, we have designed a larger scale
experiment to further confirm the observation. Briefly, a total of 24 donor mice will be
immunized twice with the Flu vaccine at a 3-week interval. Two weeks following the
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second immunization, another booster will be administered via IP route, followed by spleen
harvest and B cell enrichment 24 hours later. These B cells will then be stimulated with
LPS for 48 hours and subsequently transduced with MIG-SB-N6 pseudovirus. This B cell
population will then be evenly infused into two mouse groups: 1) immunized by following
the same vaccination schedule as donor mice or 2) unimmunized. Another group of
immunized mice will serve as a control to receive LPS-stimulated B cells transduced with
MIGR1 vector. Sera from these mice will be regularly collected and Flu immunizations
will be administered according to the time course outlined in Appendix 3.
We acknowledge that the current levels of SB-N6 being produced by transduced
cells may not be sufficient to achieve prevention efficacy. VRC01 and N6 have in vitro
neutralization potencies of 0.250ug/mL and 0.044ug/mL respectively. From our
preliminary in vivo study, we were able to achieve serum SB-N6 concentrations of well
above 0.400ug/mL; enough to provide efficient in vitro neutralization. However, most
antibodies require high serum levels, typically in the range of one to several hundred
µg/mL, to achieve therapeutic effects in vivo (118). For example, depending on the SHIV
strain and route of challenge of macaques, protective VRC01 serum concentration ranged
from 1.3ug/mL to 287ug/mL (163). To circumvent this issue, future studies will utilize a
mucosal boost strategy to enrich the activated B cells and enhance the bNAb concentration
in the vaginal mucosa which is the most common transmission site for HIV infection. In
support of this strategy, in one HIV vaccination study, it was shown that nasal vaccination
with DNA prime and protein boost could enrich B cells and antibodies in vaginal tissue in
mice (164). Additionally, we can also alter the Fc region of the SB-N6 to be IgA, which
will allow for a more efficient localization of the antibody to the mucosal membrane.
Collectively, by concentrating SB-N6 to a major site of HIV-1 transmission, it may reduce
the serum concentration needed to achieve neutralizing concentrations in the vagina.
Alternatively, we also attempted to develop an HIV specific B cell model to modulate
bNAb expression by modifying B cell to express both membrane-bound and soluble
versions of a bNAb. In theory, the MB-N6 will serve as a B cell receptor (BCR), and upon
stimulation with HIV-1 envelope, will drive expression of the SB-N6. Under normal
physiological regulation, the switch from membrane-bound form to the secreted forms of
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antibody is controlled by mRNA processing (165). Both forms can be produced through
alternative splicing and polyadenylation of a single pre-mRNA, depending on the B-cell
maturation state (165). In B cells, the membrane-bound version is preferred, and in plasma
cells, the same pre-mRNA is processed to preferentially produce the secreted version of
the antibody by replacing a hydrophobic transmembrane anchor sequence with that of a
hydrophilic C-terminal tail (165). The differentiation of a B cell to a plasma cell is
conjoined with the remodelling of cellular functions to allow efficient protein production
through the expansion of endomembrane transport network involved in the secretory
pathway (165). Fusil et al. have successfully mimicked this spatio-temporal regulation of
BCR vs secreted antibody expression by using Lentiviral vector variants and incorporating
alternative splicing and polyadenylation mechanisms regulated by cellular machinery
(165). They forced transduced-primary-B cell into plasma cells by adoptively transferring
CD19+ cells and autologous CD4+ T cells into immunodeficient mice and showed an
inverse relationship between membrane-bound and secreted versions of the tested antibody
(165). However, antigen-specific BCR stimulation was not tested to see if it drives B cell
differentiation into a pool of antibody-secreting plasma cells. In addition, Moffet et al.
utilized CRISPR/Cas9 system to replace endogenously encoded antibodies with transgene
antibodies against RSV, HIV, influenza, or EBV in primary B cells, and were able to
achieve controlled antibody production from a single gene expression cassette (166). In
our study, we were able to achieve SB-N6 production in growth media of MIG-MB-SBN6 transduced anti-p24 hybridoma cells; however, MB-N6 expression on the membrane
was not detected. By comparing intracellular expression of MB-N6 to that of cell-surface
expression, we showed that MB-N6 was in fact being produced but not transported to the
cell membrane, suggesting that the problem is likely associated with MB-N6 exportation
or the subsequent membrane-anchoring step. To troubleshoot, we will try different
antibody transmembrane/hinge domains from the literature to determine which optimally
allows for antibody fixation on the cell membrane. Additionally, we can add
polyadenylation and alternative splicing sites to mimic native antibody expression to see
whether it will improve the function of produced MB-N6.
Our study aimed to create modulated bNAb expression in vivo will not only solve
the problem on short half-life of passively transfused anti-HIV bNAbs but will also tackle
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the issue of side effects (e.g. autoimmune diseases) caused by long-term expression of
bNAbs. In the case of passive immunization, improving the half-life of bNAbs may
improve the bNAbs ability to prevent infection by neutralization due to its longer lasting
presence. Additionally, viral rebound occurs rapidly upon bNAb decay, which presents
opportunities for viral evolution. Increasing the half-life may reduce adherence
complications, in turn reducing the possibility for viral evolution, and preventing both
viremia and viral resistance. Previously, bNAb levels have been shown to decay more
rapidly in HIV-infected individuals compared to the uninfected, which may be attributed
to the formation of antibody-virus complexes that are readily recognized and cleared (122).
A promising methodology being explored to circumvent the short half-life involves the
introduction of two mutations encoding amino acid substitutions (M428L and N434S,
collectively known as LS) into genes encoding Fc domains of VRC01. Compared to its
wild-type counterpart, VRC01-LS and many iterations (now being explored in Phase I
clinical

trials;

NCT02797171,

NCT02840474,

NCT02599896,

NCT02256631)

demonstrated a 3-fold increase in its half-life, accompanied by an increase in its ability to
translocate to mucosal tissues and protection against high-dose rectal challenge in nonhuman primates (167–169). Similarly, 3BNC117-LC and 10-1074-LC have also
demonstrated to have a 2.0 and 3.8-fold increase in half life, respectively (112). Even with
this increase, repeated passive immunizations with bNAbs would be required, which is not
feasible as a large-scale anti-HIV therapeutic. Instead, through endogenous bNAb
production, our strategy involves B cell engineering to allow for long-term ability to
express anti-HIV bNAbs. Standard gene transfer therapy also has the potential to overcome
issues associated with passive immunizations; however, antibody expression achieved
through this method is uncontrollable. In studies involving the tracking of maturation from
initial B cell arrangement to breadth development, a correlation was observed between
autoreactivity and neutralization breadth of bNAbs (129). In particular, CH98, a CD4bs
targeting bNAb, was isolated from a person living with an HIV infection and systemic
lupus erythematosus (SLE). When testing the autoreactivity of CH98, it was found to be
capable of binding dsDNA, suggesting that some bNAbs derive from an autoreactive pool
of B cells (129). This combination of long-term bNAb expression and their autoreactivity
poses a significant safety concern for its use.
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To our knowledge, our study is the first to provide a mechanism for controlling the
endogenous bNAb expression, which may alleviate some degree of the autoreactivity
concerns while providing a strategy for the modulated production of anti-HIV-1 bNAbs.
Additionally, our strategy can be applied to both prophylactic and therapeutic HIV-1
vaccine fields. In the former case, an individual should receive treatment by “activating”
protection via administering an immediate flu shot when recently exposed to HIV, or when
he/she feels to be in a high-risk situation, to quickly stimulate production of anti-HIV
bNAbs. Moreover, since the modulatory effect is via the Flu vaccine, it will allow for the
anti-HIV bNAb response to be boosted yearly with the normal administration of the yearly
Flu vaccine. While this is a novel concept, the preliminary evidence generated in this study
provides a promising avenue in HIV preventative and therapeutic research.
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Appendices
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Appendix 1. Design of different forms of N6 for the construction of an HIV-1 specific
B cell model.
A diagram of the gene cassette used to express MB-N6 (A), SB-N6 (B), or both MB-SBN6 (C) from the MIGR1 vector. The sequence of murine-derived anti-p24 antibody was
used as the base for MB-N6 and SB-N6 expression vector construction. For both MB-N6
and SB-N6 generation, the anti-p24 antibody sequence was modified by replacing its LC
and HC-variable regions with that of N6. Additionally, an IgG hinge and intracellular
domain sequence was added for MB-N6. Following the MB-N6 sequence, a B cell
enhancer and vK- promoter sequence was inserted. The SB-N6 sequence immediately
follows the promoter sequence.

81

Env

1. Env binds to MB-N6
Cell membrane
4. Increased expression of SB-N6
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4. Increased transcription of SB-N6
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Appendix 2. HIV-1 specific stimulation of our B-cell model that contains both MBN6 and SB-N6.
The MB-N6 will be expressed on the cell membrane to serve as an HIV-1 specific B-cell
receptor. Once Env binds to the MB-N6, a signaling cascade will lead to B cell activation
and also lead to an increase in transcription factors able to bind to the vK- promoter. This
will increase the transcription and the subsequent expression of SB-N6, which is under the
control of the vK- promoter.
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Appendix 3. Large-scale in vivo study to test modulation of bNAb expression by Flu
vaccine.
Donor mice will be immunized twice with the Flu vaccine at a 3-week interval, with an
additional immunization administered 24 hours prior to spleen harvest and B cell
enrichment. The B cells will be stimulated with LPS for 48 hours and transduced with
MIG-SB-N6 or MIGR1. The transduced cells will then be infused intravenously into their
respective recipient mice groups. Basal SB-N6 expression will be measured, Flu
immunization will be administered for stimulation, and SB-N6 levels will again be
measured. Additional Flu stimulations will be administered in a time-sensitive manner and
sera will be collected regularly.
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